Goldman Sachs Starts Vertex (VRTX) at Buy, Sees 16% Upside
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $557.96 +0.22%
Rating Summary:
38 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 18 | New: 28
Rating Summary:
38 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 18 | New: 28
Join SI Premium – FREE
Goldman Sachs initiates coverage on Vertex (NASDAQ: VRTX) with a Buy rating and $46 price target, suggesting 16% upside.
The firm expects FDA approval of TVR for hepatitis C in May and model a 2H2011 launch. They expect the TVR launch to exceed high expectations "as the Street is underestimating the “warehoused” treatment-failure population awaiting new treatments and pricing power of TVR."
For more ratings news on Vertex click here and for the rating history of Vertex click here.
Shares of Vertex closed at $38.33 yesterday.
The firm expects FDA approval of TVR for hepatitis C in May and model a 2H2011 launch. They expect the TVR launch to exceed high expectations "as the Street is underestimating the “warehoused” treatment-failure population awaiting new treatments and pricing power of TVR."
For more ratings news on Vertex click here and for the rating history of Vertex click here.
Shares of Vertex closed at $38.33 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Adjust Monthly US Director's Cut List
- Goldman Sachs Double Upgrades Vodafone (VOD:LN) (VOD) to Buy
- Goldman Sachs Downgrades Cellnex Telecom (CLNX:SM) (CLNXF) to Sell
Create E-mail Alert Related Categories
Hot New Coverage, Insiders' Blog, New CoverageRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
